roche's risdiplam meets primary endpoint in trial of sma drug in infants
Published 4 years ago • 48 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
7:31
genentech’s risdiplam meets primary endpoint in pivotal firefish trial in infants with type 1 spi...
-
4:16
risdiplam in development for sma
-
3:35
risdiplam clinical trial data
-
6:08
four clinical trials testing risdiplam across various sma subtypes
-
4:40
clinical trials for risdiplam for sma
-
3:18
spinal muscular atrophy type 2 treatment | results
-
14:27
risdiplam day 57
-
4:04
what's sma disease and why is it's treatment so expensive? | newsmo
-
1:27
risdiplam and spinal muscular atrophy
-
2:57
3-year data from firefish demonstrates long-term safety and efficacy of risdiplam in sma type 1
-
1:59
know about primary aldosteronism (pa)
-
2:45
patient support for spinal muscular atrophy: helping patients access clinical trials worldwide
-
1:36
risdiplam’s mechanism of action
-
1:16
meet the resident: ramin morshed, md
-
2:46
gene therapy for sma type 1: evelyn's story
-
47:27
2021 virtual sma conference: understanding treatment, trials and care of a pre-symptomatic diagnosis
-
1:23:10
cure sma's community webinar on the fda approval of evrysdi risdiplam
-
4:38
risdiplam under study to treat sma
-
5:24
risdiplam: an oral treatment for spinal muscular atrophy
-
11:11
access evidence: from slrs to meta-analysis
-
1:13:56
research, clinical trials & genetic testing considerations in sma, dr richard s finkel
-
4:12
sma patient discusses his experience with risdiplam